Citations

Clear

29 citation(s) found for "Moll, M".

Venous Thromboembolism (VTE) Characteristics among White- and Black-Americans: a Cross Sectional Study
Heit, John A. , Beckman, Michele G. , Grant, Althea M., Manco‐Johnson, Marilyn J. , Moll, Stephan , Bockenstedt, Paula, Philipp, Claire S. , Key, Nigel S. , Kulkarni, Roshni , Ortel, Thomas L.

Mayo Clinic

Blood | October 14, 2019 | Volume: 112 | Issue: 11 | Pages: 3831-3831

10.1182/blood.v112.11.3831.3831 Get It

Abstract Background: Compared to Whites, Black-Americans may have a 40% higher incidence of idiopathic VTE. However, whether other VTE characteristics vary by race is uncertain. Objective: To compare demographic and baseline characteristics among White- and Black-Americans with VTE. Methods: Using a standardized data-collection form, demographic and baseline characteristics were prospectively collected from consecutive consenting patients enrolled in seven Thrombosis and Hemostasis Centers from August 2003 to March 2008. For patients with objectively diagnosed VTE, demographic and baseline characteristics were compared among White- and Black-American VTE patients, both overall, and by age and gender. Results: Among 1960 White- and 368 Black-Americans with VTE, compared to Whites, Blacks had significantly less isolated DVT (73.9% vs. 86.5%, p<0.001) and significantly more PE ± DVT (45.1 vs. 39.6%, p=0.05). Blacks and Whites did not differ in mean age (43.4 vs. 44.3 years), but a significantly higher proportion of Black men VTE patients were in age groups 20–39 and 80+ years. Blacks and Whites differed significantly by gender, with a significantly higher proportion of Black women with VTE (69.8% vs. 59.1%, p=0.0001). Blacks had a significantly higher mean BMI (32.3 vs. 29.4 kg/m2, p<0.0001), a significantly lower proportion with recent surgery or trauma, active cancer and infection, and a significantly lower proportion with a family history of VTE or documented thrombophilia (solely due to reduced Factor V Leiden and Prothrombin G20210A prevalence). Conversely, Blacks had a significantly higher proportion with hypertension, hyperlipidemia, diabetes mellitus, chronic renal disease and dialysis, HIV and sickle cell disease. The two races did not differ significantly regarding the proportion with idiopathic VTE, CHF, CAD/MI, peripheral artery disease, stroke or other chronic neurological disease (i.e., cerebral palsy), chronic liver disease or autoimmune disease, including antiphospholipid syndrome. Compared to White women VTE patients, Black women VTE patients had a significantly lower proportion with recent surgery, trauma, infection, oral contraceptive use and possibly hormone therapy; and a significantly higher proportion with idiopathic VTE, hypertension, diabetes mellitus, chronic renal disease, HIV and sickle cell disease. Compared to White men VTE patients, Black men VTE patients did not differ significantly regarding recent surgery, trauma, cancer, infection or autoimmune disease, but Black men had a significantly higher proportion with hypertension, diabetes mellitus, HIV and sickle cell disease. Black and White men with VTE did not differ significantly regarding idiopathic VTE, CHF, CAD/MI, stroke, peripheral arterial disease and chronic renal disease. Conclusion: White- and Black-Americans with VTE differ significantly regarding demographic and baseline characteristics that may be risk factors for VTE.
Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.
Manco‐Johnson, Marilyn J. , Beckman, Michele G. , Goldenberg, Neil A. , Michaels, Lisa A., Pipe, Steven W. , Moll, Stephan , Rodriquez, Vilmarie, Thornburg, Courtney D. , Kulkarni, Roshni

Mayo Clinic

Blood | October 13, 2019 | Volume: 114 | Issue: 22 | Pages: 4000-4000

10.1182/blood.v114.22.4000.4000 Get It

Abstract Abstract 4000 Poster Board III-936 Background There is insufficient information regarding the epidemiology and outcomes of DVT in children. The CDC began a consented registry in August 2003 at eight pilot Centers for Thrombosis and Thrombophilia including six pediatric sites in order to assess the scope and severity of DVT morbidity in children. Methods Data for this analytic project were extracted from the CDC thrombosis registry. We performed a nested case-control study within the registry cohort. Children and adults are eligible to enroll onto this consented registry if they have a history of thrombosis, thrombophilia or a positive family history or either. DVT site, extent, recurrence and BMI were determined clinically. In addition, thrombophilia testing batteries, imaging protocols and determinations of PTS outcomes of DVT were made locally and criteria were not standardized among participating centers. Results As of March 2009 the CDC registry included 316 cases of DVT in infants and children (ages 0-21), and 2414 cases in adults (> 21). There were 16 cases reported to have lower extremity (LE) PTS in children and 184 in adults. Table 1 displays effects of thrombus site, recurrence and BMI on PTS prevalence. The proportion of LE DVT involving the inferior vena cava (IVC) was 5.5-fold higher in children compared to adults (11% vs 2%). Furthermore, among cases of IVC involvement, the prevalence of PTS following IVC thrombosis was remarkably higher in children compared with adults (38.9 vs 6.3%, P < 0.001). The prevalence of PTS following LE DVT overall in children did not differ from adults. Results for upper extremity DVT and resultant PTS were similar. Fifteen percent of children had recurrence. Increasing number of DVT events was associated with an increased risk of PTS. BMI was higher in children who developed PTS (p = 0.06; BMI > 28, OR 3.3 [1.08, 9.59]). In addition, thrombophilia was a risk factor for developing PTS in children (p = 0.02; OR = 2.9 [CI 1.03, 8.05]), with the highest risk determined with antiphospholipid syndrome (p = 0.02; OR = 3.4 [1.09, 9.93]) and protein C deficiency (p = 0.02, OR = 10.9 [0.84, 99.3]). Discussion Children with LE DVT demonstrate a high rate of IVC thrombosis, and a higher relative risk of PTS in cases of IVC involvement. Elevated BMI and thrombophilia augment the risk of PTS in children. The limitations of this study include the lack of standardization in DVT diagnostic and PTS evaluations. The study findings support application of standardized approaches to the diagnosis and follow-up evaluation of children with DVT in order to more meaningfully determine outcomes for future interventive trials. Disclosures: Moll: Ovation: Consultancy; GTC Biotherapeutics: Consultancy; Talecris: Consultancy.
Identification of Patients At High Risk for Recurrent Venous Thromboembolism by Whole Blood Gene Expression Analysis
Beckman, Michele G. , Hooper, W. Craig, Lewis, Deborah , Jen-Tsan, A., Kenney, Kristy , Staercke, Christine De , Heit, John A. , Moll, Stephan , Philipp, Claire S. , Manco‐Johnson, Marilyn J. , Ortel, Thomas L.

Mayo Clinic

Blood | October 13, 2019 | Volume: 118 | Issue: 21 | Pages: 2305-2305

10.1182/blood.v118.21.2305.2305 Get It

Abstract Abstract 2305 Background. Recurrent venous thromboembolism (VTE) occurs in ∼30% of patients with spontaneous VTE after completion of a standard course of anticoagulant therapy. D-dimer levels and selected clinical parameters have been used to identify patients at low risk for recurrent VTE, who may safely discontinue antithrombotic therapy. We have used gene expression profiles to distinguish patients with a single VTE from patients with recurrent VTE. The purpose of this study was to extend this initial report and identify unique gene expression patterns from whole blood that correlate with different risk profiles for VTE recurrence. Methods. Patients with ≥1 prior VTE, with the first event occurring at age 18 years or older and >3 months from the most recent event were recruited for this study. Patients were allocated into 4 groups: (1) ‘low-risk’ patients had sustained ≥1 provoked VTE; (2) ‘moderate-risk’ patients had sustained 1 unprovoked VTE (with or without provoked VTE); (3) ‘high-risk’ patients had sustained ≥2 unprovoked VTE and had no evidence for antiphospholipid antibodies; and (4) antiphospholipid syndrome (APS) patients met established consensus criteria for APS. A similar number of individuals with no prior history of VTE were enrolled as a control population. Citrated plasma, serum and PAXgene RNA tubes were collected, processed and stored at −80°C until shipped to the CDC for analysis. Antiphospholipid testing was performed on all participants to confirm correct group distribution. Total RNA was isolated from whole blood drawn into PAXgene tubes. Following sample labeling and normalization, cRNA samples were hybridized to Illumina HT-12 Beadchips to assay whole genome gene expression with over 47,000 probes against human transcripts. Two hundred and twenty six unique samples passed initial quality control measures. Quality assessment of raw data was done using GenomeStudio. The raw data files were converted to a text file using the IlluminaExpression FileCreator in GenePattern and then log transformed, normalized and median-centered using Cluster. Both unsupervised (hierarchical clustering using Cluster) and supervised analyses (SAM) were used to identify genes that were differentially expressed between the groups. GATHER was used to help understand the biological processes and gene ontology of the gene lists generated by Cluster and SAM. Results. A total of 226 participants were enrolled into the study. Characteristics of the patient groups are summarized in the Table. Demographically, the groups were similar except that patients in the high-risk group tended to be older and were more likely male. The number of events per patient, and the proportion on anticoagulant therapy, increased with the risk group. Antiphospholipid antibodies were detected in several patients in each of the 3 non-APS VTE patient groups, but in most cases this was a single test positive; antiphospholipid antibodies were present in the majority of patients with APS, typically with more than one test positive (37 of 45 with complete testing, 82%). Preliminary analysis of the gene expression profiles using an unsupervised clustering by gene on the high-risk and low-risk groups identified multiple genes that distinguished the two groups, including 18 immune response genes identified by GATHER. These two patient groups were also distinguished by SAM analysis, and multiple genes in the MAPK signaling pathway that separated the two groups were identified by the KEGG pathways in GATHER. Additional analyses are being performed on all of the groups. Conclusions. Whole blood gene expression profiling can be used to develop profiles that distinguish patients with VTE who differ based on their risk of recurrent events. Individual genes identified in these profiles may provide biological insights into the molecular basis for recurrent VTE. Disclosures: Heit: Daiichi Sankyo: Honoraria; Ortho-McNeil Janssen: Honoraria; Covidien: Honoraria. Manco-Johnson:Octapharma AG: Consultancy; Bayer: Research Funding.
Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients
Beckman, Michele G. , Bockenstedt, Paula, Heit, John A. , Manco‐Johnson, Marilyn J. , Moll, Stephan , Philipp, Claire S. , Andersen, Judith C., Landi, Daniel B. , Shah, Nirmish , Kulkarni, Roshni , Ortel, Thomas L.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 4219-4219

10.1182/blood.v116.21.4219.4219 Get It

Abstract Abstract 4219 Background: Clinical characteristics associated with abdominal vein thrombosis (including hepatic, portal, and mesenteric veins; renal veins; and inferior vena cava [IVC]) overlap with characteristics associated with deep vein thrombosis (DVT) in the legs and pulmonary embolism (PE) but also possess unique attributes. These characteristics may differ between adult and pediatric patient groups. Methods: Using a standardized data-collection form, demographic and baseline characteristics were prospectively collected from consecutive consenting patients enrolled within one of seven Thrombosis and Hemostasis Centers over a seven-year period, August 2003 to June 2010. Patients with intra-abdominal venous thrombosis (defined as abdominal and renal veins, and IVC) were divided into pediatric (age <18 years) and adult (age ≥18 years) groups and compared to patients in the same age ranges with lower extremity DVT and/or PE. RESULTS: As of June 2010, the Patient Registry contained a total of 3105 patients with venous thromboembolism (VTE). A total of 270 patients had intra-abdominal thrombosis (9%) compared to 2276 with lower extremity DVT and/or PE (73%). Of the intra-abdominal clots, pediatric patients were more likely to have IVC thrombus (22 of 42; 52%) than adults (38 of 228; 17%; p<0.0001); conversely, pediatric patients were less likely to have hepatic, portal, and mesenteric thrombosis (n=25; 60%) than adults (n=195; 86%, p<.0001). For adult patients, proportionately more women had abdominal thrombosis (157 of 228; 68.9%) than DVT/PE (1306 of 2140; 61%; p=0.02); in contrast, comparable numbers of female pediatric patients had abdominal thrombosis (20 of 42; 47.6%) and DVT/PE (68 of 136; 50%). The mean age for patients having abdominal thrombosis was lower than patients having DVT/PE for both adults (38.3 vs 43.0 yrs; p<0.0001) and pediatric patients (9.0 vs 11.9 yrs; p=0.014). Similarly, the mean body mass index was lower for patients having abdominal thrombosis than patients having DVT/PE for both adults (28.1 vs 30.8; p<0.0001) and pediatric patients (21.5 vs. 24.7; p=0.05). There were no relationships with race, ethnicity, or inherited thrombophilic disorders. In adults, autoimmune conditions (21.9 vs 13.6; p=0.0007) and recent surgery (14.0 vs 9.2; p=0.02) were more common in patients with abdominal thrombosis, whereas, hyperlipidemia was more frequent in patients with DVT/PE (8.3 vs 13.2; p=0.04). None of these relationships were seen in the pediatric patients, but trauma was more frequently seen in pediatric patients with DVT/PE than abdominal thrombosis. Sixty-one adult (26.8%) and 6 pediatric patients (14.3%) had another VTE elsewhere, with most occurring after the initial event (21 DVT and 7 PE). Similar proportions of adult and pediatric patients had arterial thromboembolic events for both abdominal thrombosis and DVT/PE. CONCLUSIONS: Adult patients with abdominal thrombosis are more likely female, have hepatic, portal and/or mesenteric vein thrombosis, and common co-morbid conditions include recent surgery and autoimmune disorders. Pediatric patients are evenly divided between male and female, more commonly have IVC thrombosis, and co-morbid conditions include recent trauma. Both adult and pediatric patients with abdominal thrombosis tend to be younger and have a lower BMI than patients with DVT and/or PE. We also found a high rate of concurrent thrombosis in both adult and pediatric patients with abdominal thrombosis. In summary, patients with abdominal thrombosis display different clinical characteristics when compared to those with DVT/PE, specifically in terms of gender, location of thrombosis, and associated co-morbidities. Some of these differences, such as higher rates of IVC thrombosis in pediatric patients with abdominal thrombosis, might be caused by variance between genetic and anatomic factors. Further studies are warranted to explain these differences. Disclosures: Kulkarni: Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Participate in clinical trials. Philipp:Baxter: Research Funding; Wyeth: Research Funding; Octapharma: Research Funding. Ortel:Sanofi-Aventis: Consultancy, Research Funding; Ortho-McNeil: Consultancy; GlaxoSmithKline: Research Funding; Eisai: Research Funding; Pfizer: Research Funding.
Validation of insorption by blood analysis with comparisons of systemic and portal venous disappearances of D2O, Na24, and K42
Code, Charles F., Moll, Johann C., Orvis, Alan L.

Mayo Clinic

Journal of Applied Physiology | December 24, 2017 | Volume: 18 | Issue: 4 | Pages: 829-832

10.1152/jappl.1963.18.4.829 | PMID 14021916 Get It

The rates of disappearance D2O, Na22/24 and K42 from the arterial blood were determined in 17 dogs following rapid injection of the isotopes into the femoral and portal veins. Differences between systemic and portal venous injections were significant during the early phases of the disappearance of the isotopes (P < 0.05). Systemic insorption was simulated by continuous intravenous injection of D2O, Na22, and K42 at known rates into the femoral vein. The appearance of the isotopes in the arterial blood was determined repeatedly during and after their injection. The rate of injection (simulated insorption) was calculated using the mean systemic arterial disappearance rate. The differences between the calculated and actual rates of injection were insignificant. When portal insorption was simulated by constant injection of the isotope into the portal vein, the calculated rate of injection was not significantly different from the actual rate if the mean portal arterial disappearance curve was used in the calculation. When the systemic arterial disappearance curve was utilized, the calculated rate of injection was slightly faster than the actual rate. Submitted on July 11, 1962
Rates of insorption of sodium and potassium from stomachs of rats
Moll, Johann C., Code, Charles F.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 21, 2017 | Volume: 203 | Issue: 2 | Pages: 229-231

10.1152/ajplegacy.1962.203.2.229 | PMID 14475197 Get It

This study was undertaken to determine rates of insorption of radiosodium and radiopotassium from secreting and nonsecreting stomachs of rats. The methods employed have been described previously. Insorption of radiosodium from gastric contents to blood was always faster in nonsecreting than in acid-secreting stomachs. At the end of 15, 30, and 45 min the mean percentages insorbed from stomachs secreting acid were 1.6, 3.1, and 4.5, whereas from stomach not secreting acid the mean percentages were 5.8, 9.3 and 11.7, respectively. In contrast, the rate of insorption of radiopotassium was unaffected by presence or absence of acid. Its rate of insorption was uniformly low and about equal to the rate of insorption of radiosodium from the secreting stomach. The results demonstrate that the rat's stomach, like that of man and dog, offers a barrier to insorption of sodium which is more pronounced when acid is being secreted and that insorption of potassium, though slow, is unaffected by acid and most likely is independent of insorption of sodium.
Rates of insorption of sodium and potassium from upper small bowel of rats
Moll, Johann C., Code, Charles F.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 21, 2017 | Volume: 203 | Issue: 2 | Pages: 225-228

10.1152/ajplegacy.1962.203.2.225 | PMID 14475198 Get It

Rates of insorption of radiosodium and radiopotassium from the unobstructed small bowel of rats were determined and compared with those obtained by others in healthy humans. Insorption of the isotopes under study was estimated by integration of their rates of appearance in the blood after placement in the small bowel and their rates of disappearance from blood after injection into the circulation. The rates of disappearance from arterial blood were determined during separate tests. They followed an exponential pattern similar though not identical with that reported from other species by other investigators. Radiosodium was insorbed more rapidly than radiopotassium. Mean values indicated that 50% of administered radiosodium was insorbed within 6–7 min, whereas 26–27 min were required for insorption of 50% of the radiopotassium. The rate constant during insorption of the first 76% of the Na22 was 10.8% per min and that for insorption of 58% of the K42 was 2.7% per min.
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol
Schünemann, Holger J. , Ventresca, Matthew, Briel, Matthias , García, David , Noble, Simon , Macbeth, Fergus , Griffiths, Gareth , DiNisio, Marcello, Iorio, Alfonso , Beyene, Joseph, Mbuagbaw, Lawrance, Es, Nick van , Brouwers, Melissa , Brożek, Jan , Levine, Mark N. , Moll, Stephan , Streiff, Michael B. , Baldeh, Tejan , Flórez, Iván D. , Alma, Özlem Gürünlü , Solh, Ziad , Ageno, Walter , Marcucci, Maura , Bozas, George , Zulian, Gilbert B., Lebeau, B, Büller, Harry R. , McBane, Robert D. , Bleker, Suzanne M. , Pelzer, Uwe , Iorio, Alfonso , Crowther, Mark Andrew , Zhou, Qi Xin , Lyman, Gary H , Neumann, Ignacio , Guyatt, Gordon , Santesso, Nancy A. , Maraveyas, Anthony , Evans, Jessica , Akl, Elie A. , McBane, Robert , Schünemann, Holger J , Ageno, Walter

Mayo Clinic

BMJ Open | April 29, 2016 | Volume: 6 | Issue: 4 | Pages: e010569

10.1136/bmjopen-2015-010569 | PMID 27130164 Get It

Introduction Parenteral anticoagulants may improve outcomes in patients with cancer by reducing risk of venous thromboembolic disease and through a direct antitumour effect. Study-level systematic reviews indicate a reduction in venous thromboembolism and provide moderate confidence that a small survival benefit exists. It remains unclear if any patient subgroups experience potential benefits. Methods and analysis First, we will perform a comprehensive systematic search of MEDLINE, EMBASE and The Cochrane Library, hand search scientific conference abstracts and check clinical trials registries for randomised control trials of participants with solid cancers who are administered parenteral anticoagulants. We anticipate identifying at least 15 trials, exceeding 9000 participants. Second, we will perform an individual participant data meta-analysis to explore the magnitude of survival benefit and address whether subgroups of patients are more likely to benefit from parenteral anticoagulants. All analyses will follow the intention-to-treat principle. For our primary outcome, mortality, we will use multivariable hierarchical models with patient-level variables as fixed effects and a categorical trial variable as a random effect. We will adjust analysis for important prognostic characteristics. To investigate whether intervention effects vary by predefined subgroups of patients, we will test interaction terms in the statistical model. Furthermore, we will develop a risk-prediction model for venous thromboembolism, with a focus on control patients of randomised trials. Ethics and dissemination Aside from maintaining participant anonymity, there are no major ethical concerns. This will be the first individual participant data meta-analysis addressing heparin use among patients with cancer and will directly influence recommendations in clinical practice guidelines. Major cancer guideline development organisations will use eventual results to inform their guideline recommendations. Several knowledge users will disseminate results through presentations at clinical rounds as well as national and international conferences. We will prepare an evidence brief and facilitate dialogue to engage policymakers and stakeholders in acting on findings. Trial registration number PROSPERO CRD42013003526.
Insulinemia in Children at Low and High Risk of NIDDM
Pettitt, David J. , Moll, Patricia P., Knowler, William C. , Mott, David M., Nelson, Robert G. , Bennett, Peter H. , Kottke, Bruce A., Saad, Mohammed F.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 16 | Issue: 4 | Pages: 608-615

10.2337/diacare.16.4.608 | PMID 8462388 Get It

OBJECTIVE Fasting hyperinsulinemia in the presence of normoglycemia usually indicates insulin resistance and is characteristic of populations at high risk for developing NIDDM. Hyperinsulinemia predicts the development of impaired glucose tolerance and NIDDM in Pima Indians, a population with a high incidence of NIDDM. Insulin concentrations in population-based samples of children who have different risks of developing NIDDM later in life have not been reported previously. RESEARCH DESIGN AND METHODS We compared fasting insulin concentrations in two populations of nondiabetic children, 6–19 yr of age: Pima Indians from southern Arizona and Caucasians from Minnesota. RESULTS Insulin concentration varied with age, sex, glucose concentration, and relative weight. Mean fasting insulin concentration was 140.3 pM in Pima Indian males, 94.4 pM in Caucasian males, 171.5 pM in Pima Indian females, and 107.1 pM in Caucasian females. For each sex, the mean fasting insulin concentration, controlled for age, glucose, and relative weight, was significantly higher in the Pima Indians than in the Caucasians (P &lt; 0.001). CONCLUSIONS From a young age, Pima Indian children have higher fasting insulin concentrations than Caucasian children. As hyperinsulinemia predicts subsequent NIDDM, these data suggest that the susceptibility to NIDDM is manifest at a young age as fasting hyperinsulinemia.